60 results about "Minimal promoter" patented technology

This invention relates to novel adenoviruses useful in the production of high titers of recombinant adeno-associated virus (rAAV) comprising a foreign DNA insert and methods of making these adenoviruses. The adenovirus comprises the AAV rep gene in which the p5 promoter is replaced by a minimal promoter or by no promoter. The invention also provides methods of producing high levels of rAAV as a substantially homogenous preparation and composition of rAAV.

The present application discloses a method for making and selecting a transcription enhancing combined promoter cassette, which includes constructing a library of randomly combined transcription regulatory elements, which comprise double stranded DNA sequence elements that are recognized by transcription regulators; inserting the combined transcription regulatory elements upstream of a minimum promoter followed by a reporter gene in a vector; inserting the vector into a host cell; and then screening for the cells showing enhanced expression of the reporter gene, and identifying the combined promoter cassette in the cell.

Late embryogenesis abundant (Lea) proteins accumulate in maturing seeds after many of the storage compounds have been synthesized, and they are considered relevant to maturation. We report here the molecular organization and expression of BnLea3-1, a novel Group 3 Lea gene from Brassica napus. BnLea3-1 contains a coding region of 798 bp, sharing 84.4% homology at the amino acid level with Lea76 of B. napus. Two tandem 11-mer repeats are truncated from the coding region of BnLea3-1, compared to the 13 conserved 11-mer repeats of Lea76. Substitutions of consensus residues are found at various positions within the 11-mer repeats. A 1561 bp 5′ flanking promoter fragment of BnLea3-1 fused to E. coli-glucuronidase (GUS) coding region conferred seed-specific GUS expression in stable transgenics of B. napus, tobacco and in transiently-transformed pea. A −137 bp minimal promoter preceding the first transcription start site, identified through progressive deletions from the upstream was sufficient for basal GUS expression in the seeds and in leaves treated with ABA. Deletion studies indicate the presence of enhancing elements located between −137 bp to −742 bp and suppressing elements located between −742 and −1561 bp. BnLea3-1 expression in seeds precedes that of Lea76. Unlike other Group 3 Lea members including HVA1 and Dc3, BnLea3-1 is active in seeds and responsive weakly in vegetative tissues to ABA and methyl jasmonate (MeJA) but not to stress treatments. Possible functions of BnLea3-1 and another member of the Group 3 Lea family BnLea3-2 in embryo development is discussed.

The invention discloses a gene expression vector for adjusting and controlling NF-kB activity in cells as well as a regulation and control method and application of the gene expression vector. The vector comprises two sequence elements, a promoter sequence and an miRNA coding sequence, wherein the promoter sequence is used for adjusting and controlling gene expression, and the miRNA coding sequence is located at the downstream of a promoter; the promoter sequence is formed by a section of NF-kB trapper sequence and a minimal promoter sequence; the miRNA coding sequence is the miRNA coding sequence capable of encoding and targeting NF-kB miRNA. By transfecting the gene expression vector, the NF-kB activity in the overactive cells can be mildly and effectively reduced, and the activity of normal cells is not obviously influenced, so that the side effect is avoided. The regulation and control method of the gene expression vector is simple, rapid and effective; and the gene expression vector is used for preparing an NF-kB activity regulation and control reagent or a drug molecule for treating diseases closely related to NF-kB overactivity and is taken as a novel gene treatment reagent.

The invention discloses a NF-kappa B specifically activated gene expression vector and application thereof. A gene expression technique is implemented by the NF-kappa B specifically activated gene expression vector. The gene expression vector contains two elements, i.e., a regulatory gene-expressed promoter sequence and a promoter downstream effect gene coding sequence, wherein the promoter sequence consist of a section of NF-kappa B response sequence and a minimal promoter sequence. After the gene expression vector is introduced into NF-kappa B overactivated cells, an effect gene on the vector is expressed under the activation of a sequence-specific transcription factor NF-kappa B, and the effect gene generates influence on cell physiology, such as cell growth inhibition, apoptosis and death. The gene expression technique provided by the invention can be used for treating diseases related to NF-kappa B overactivation, such as inflammation and cancers. The gene expression vector constructed by the invention can be used in the preparation of gene therapy reagents and drugs for treating diseases related to NF-kappa B overactivation.

Methods and compositions are provided for modulating, and generally upregulating, the expression of telomerase reverse transcriptase (TERT) by blocking repression of TERT transcription, e.g., by inhibiting binding of repressor factor to a Site C repressor binding site located in the TERT minimal promoter. The subject methods and compositions find use in a variety of different applications, including the immortalization of cells, the production of reagents for use in life science research, therapeutic applications; therapeutic agent screening applications; and the like. In further describing the subject invention, the methods and compositions of the invention are described first in greater detail, followed by a review of the various applications in which the subject invention finds use.

Telomerase repressor proteins and nucleic acid compositions encoding the same are provided. The subject repressor proteins bind to a repressor site in the TERT minimal promoter, e.g., a Site C site, and thereby inhibit TERT expression. Also provided are methods of modulating, e.g., inhibiting or enhancing, TERT expression. The subject invention finds use in a variety of different applications, including therapeutic and therapeutic agent screening applications.

A gene expression system for controllable expression of ethylene response in a plant cell includes an activation cassette comprising a DNA-binding domain that recognizes a response element; an ecdysone receptor ligand binding domain; and an activation domain; and a target cassette comprising an inducible promoter, which comprises, in operative association, the response element and a minimal promoter responsive to the activation domain. The inducible promoter controls the expression of a nucleic acid sequence that encodes a selected protein that modifies sensitivity to ethylene in the plant. Interaction among the components of the activation cassette and target cassette, when in a plant cell, in the presence of an inducing composition, modulates expression of the selected protein and selectively modulates ethylene sensitivity in the plant cell. This modulation in the expression of the protein is controlled by the timing, the concentration and the duration of the application of the inducing composition. Transgenic plant cells, tissues, organs and entire plants are provided, which in the presence of the inducing composition control ethylene sensitivity. Ethylene sensitivity and/or ethylene production in such transgenic plants and tissues may be controlled for purposes of manipulating ripening, flower senescence and other ethylene sensitive functions of the plant.

Provided is a test method that allows mutagenicity on a mammal including a human to be confirmed accurately and simply in a short time. Specifically, provided is a mutagenicity test method, including the steps of: (1) culturing a transformant of a mammalian cell harboring a recombinant vector including a p53 binding sequence, a minimal promoter that can function in the mammalian cell, and a reporter gene linked so that the gene can be expressed by the minimal promoter, in the presence of a test substance for a predetermined time; and (2) assessing whether or not the test substance affects an expression amount of the reporter gene in the transformant by comparing an expression amount of the reporter gene in the transformant cultured in the step (1) to an expression amount of the reporter gene in the transformant free of contact with the test substance.

The present invention relates to a method for conferring tolerance to salt stress and drought stress in a monocot plant including transforming the monocot plant with an expression cassette comprising at least one ABRC unit, a minimal promoter, and a DNA molecule that increases tolerance to salt stress and drought stress in plants, wherein the at least one ABRC unit, the minimal promoter, and a DNA molecule are operably linked together to permit expression of the DNA molecule. The present invention also relates to a transgenic monocot plant transformed with a DNA molecule that increases tolerance to salt stress and drought stress operably linked to at least one ABRC unit and a minimal promoter.

The invention provides a transcriptional promoter for the human BACE1 gene as well as a core promoter region and cis-acting elements of the transcriptional promoter. According to the invention, the smallest promoter region defining the high-level transcription of the human BACE1 gene and the core promoter region defining basal transcription of the human BACE1 gene are firstly confirmed, and the two cis-acting elements capable of enhancing gene transcription are confirmed, the structure of the BACE1 gene promoter core region playing a key function on the transcription of the BACE1 gene is disclosed, and a transcription regulatory mechanism of the BACE1 gene and influence, found through the transcription regulatory mechanism, on the transcription and expression of the BACE1 gene are understood more deeply. Effective action target spots are provided for preventing, diagnosing and treating AD and other diseases.

Nucleic acid compositions comprising a region and a TERT minimal promoter activator binding site that acts to activate transcription of the telomerase reverse transcriptase (TERT) coding sequence, as well as vectors and constructs including the same, are provided. Also provided are methods of modulating, e.g., inhibiting, the TERT transcription activation activity of the subject TERT activator binding site regions in order to regulate, e.g., repress, telomerase expression, which methods find use in a variety of different applications, including the therapeutic applications and the like. In addition, methods of screening for agents that modulate the TERT transcription activating activity of the subject TERT activator sites are provided. The subject invention finds use in, among other applications, the regulation of TERT expression.

The invention belongs to the technical field of biology, and discloses a minimum promoter for enhancing activity and expression of exogenous protein in bacteria. According to the minimum promoter, the minimum promoter capable of enhancing the activity and the expression of the exogenous protein in the bacteria is screened in a deletion mutation manner, and the minimum promoter is 265 nucleotides on the upstream of a gene coding region of salmonella enteric subspecies enteric chlamydia mouse typhimurium strain RM13672SspH1, and the nucleotide sequence of the minimum promoter is represented by SEQ.ID.NO: 1. The obtained minimum promoter for enhancing the activity and expression of the exogenous protein in the bacteria still keeps activity in escherichia coli, is a promoter with general activity, has the potential to be applied to other different types of prokaryotic bacteria, and can be used as a tool for improving the protein yield and the protein activity in the industry or scientific research, and scientific research, biological medicine industrial production and preparation of anti-infectious disease vaccines are facilitated.

A binary vector and the provision of expression of a target antigen-dependent regulatory cytokine using the synNotch technology, so as to partially release the cytokine to enhance the function of T cell and reduce the non-specific toxic and side effect of the cytokine. A synthetic notch receptor is used to construct plasmid vectors to achieve local cytokine secretion. One plasmid vector uses a specific antibody as an extracellular domain for identifying a target antigen, a notch core comprises a transmembrane domain and a specific enzyme cutting site on a notch receptor, and transcription factor GAL4VP64 is used as an intracellular domain. When the target antigen is identified, the enzyme cutting site on the notch will be identified by a corresponding enzyme to hydrolyze and cut the intercellular transcription factor GAL4VP64. Another plasmid vector carries DNA identification/binding domain GAL4UAS of transcription factor GAL4 and correspondingly activates a minimal promoter of a target gene, and after being hydrolyzed and cut, GAL4VP64 will be bound to the binding domain to activate transcription of subsequent genes so as to express IL12 and secrete same out of the cell.